KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Research & Development: 2009-2025

Historic Research & Development for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $198.2 million.

  • Jazz Pharmaceuticals' Research & Development fell 0.86% to $198.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $819.3 million, marking a year-over-year decrease of 4.75%. This contributed to the annual value of $884.0 million for FY2024, which is 4.04% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Research & Development stood at $198.2 million, which was up 9.72% from $180.7 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Research & Development peaked at $240.5 million during Q4 2024, and registered a low of $76.6 million during Q1 2021.
  • For the 3-year period, Jazz Pharmaceuticals' Research & Development averaged around $211.3 million, with its median value being $212.9 million (2023).
  • Per our database at Business Quant, Jazz Pharmaceuticals' Research & Development surged by 79.33% in 2021 and then decreased by 18.16% in 2025.
  • Jazz Pharmaceuticals' Research & Development (Quarterly) stood at $155.4 million in 2021, then climbed by 11.01% to $172.6 million in 2022, then grew by 25.53% to $216.6 million in 2023, then rose by 11.03% to $240.5 million in 2024, then declined by 0.86% to $198.2 million in 2025.
  • Its Research & Development was $198.2 million in Q3 2025, compared to $180.7 million in Q2 2025 and $240.5 million in Q4 2024.